CN100572365C - 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 - Google Patents
用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 Download PDFInfo
- Publication number
- CN100572365C CN100572365C CNB2006100165781A CN200610016578A CN100572365C CN 100572365 C CN100572365 C CN 100572365C CN B2006100165781 A CNB2006100165781 A CN B2006100165781A CN 200610016578 A CN200610016578 A CN 200610016578A CN 100572365 C CN100572365 C CN 100572365C
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- triazolo
- quinoline
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 16
- 229960003965 antiepileptics Drugs 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims abstract description 8
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- GTZOZDOTOWNSJH-UHFFFAOYSA-N [O].CCCCCCC Chemical compound [O].CCCCCCC GTZOZDOTOWNSJH-UHFFFAOYSA-N 0.000 claims description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 238000004073 vulcanization Methods 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 11
- 206010044221 Toxic encephalopathy Diseases 0.000 description 11
- 230000007135 neurotoxicity Effects 0.000 description 11
- 231100000228 neurotoxicity Toxicity 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 230000003556 anti-epileptic effect Effects 0.000 description 7
- KXZSVYHFYHTNBI-UHFFFAOYSA-N 1h-quinoline-2-thione Chemical class C1=CC=CC2=NC(S)=CC=C21 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- -1 Carbamzepine Chemical compound 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- DYMKTSBPDKZXQR-UHFFFAOYSA-N 6-phenylmethoxy-3,4-dihydro-1h-quinoline-2-thione Chemical class C=1C=C2NC(=S)CCC2=CC=1OCC1=CC=CC=C1 DYMKTSBPDKZXQR-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 125000003545 alkoxy group Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 125000003118 aryl group Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical class *C#N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010572 single replacement reaction Methods 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical class [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100165781A CN100572365C (zh) | 2006-01-26 | 2006-01-26 | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100165781A CN100572365C (zh) | 2006-01-26 | 2006-01-26 | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1807419A CN1807419A (zh) | 2006-07-26 |
CN100572365C true CN100572365C (zh) | 2009-12-23 |
Family
ID=36839533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100165781A Expired - Fee Related CN100572365C (zh) | 2006-01-26 | 2006-01-26 | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100572365C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018260B2 (en) * | 2012-06-21 | 2015-04-28 | Eisai R&D Management Co., Ltd. | Indanesulfamide derivatives |
CN102887910B (zh) * | 2012-08-27 | 2016-08-24 | 全哲山 | 用作抗癫痫药的7-烷氧基-[1,2,4]三唑并[3,4-b]苯并噻唑-3(2H)-酮衍生物及其制备方法 |
CN104194250B (zh) * | 2014-09-16 | 2016-06-22 | 江阴润玛电子材料股份有限公司 | 一种电路用导电塑料的制备方法 |
CN104522002A (zh) * | 2014-12-31 | 2015-04-22 | 江阴苏利化学股份有限公司 | 一种含有喹啉酮的防治水稻二化螟的农药组合物的新应用 |
CN104430409A (zh) * | 2014-12-31 | 2015-03-25 | 江阴苏利化学股份有限公司 | 一种含有喹啉酮的防治水稻二化螟的农药组合物 |
US11660275B2 (en) | 2018-03-20 | 2023-05-30 | Eisai R&D Management Co., Ltd. | Epilepsy treatment agent |
-
2006
- 2006-01-26 CN CNB2006100165781A patent/CN100572365C/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Internuclear cyclizatons in s-triazoles. Naqui,S.,et al.Tetrahedron Letters. 1962 |
Internuclear cyclizatons in s-triazoles. Naqui,S.,et al.Tetrahedron Letters. 1962 * |
Retrospective quantitative structure-activity relationship(QSAR) analysis of tetrazolo- and triazoloquinolines, a seriesof rice blast control agents. Dreikorn, Barry A., Durst, Gregory L.ACS Symposium Series,Vol.584 . 1995 |
Retrospective quantitative structure-activity relationship(QSAR) analysis of tetrazolo- and triazoloquinolines, a seriesof rice blast control agents. Dreikorn, Barry A., Durst, Gregory L.ACS Symposium Series,Vol.584 . 1995 * |
Also Published As
Publication number | Publication date |
---|---|
CN1807419A (zh) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100572365C (zh) | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 | |
CN102093360B (zh) | 二氢蝶啶酮衍生物的制备方法 | |
ES2727815T3 (es) | Tratamiento del TEPT y de trastornos del control de impulsos | |
CN102206180B (zh) | 作为多聚(adp-核糖)聚合酶抑制剂的被取代的6-环己基烷基取代的2-喹啉酮和2-喹喔啉酮 | |
CN102892288B (zh) | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物,组合物,以及其治疗神经学上的功能失调的方法 | |
EP2841431B2 (en) | Dihydrate of benzothiophene compound and process for producing the same | |
CN1910154B (zh) | 用作分枝杆菌抑制剂的喹啉衍生物 | |
CN102164488B (zh) | 有益于治疗中枢神经系统疾病和病症的新化合物 | |
CN102369202A (zh) | 氮杂喹啉酮衍生物及其应用 | |
EP3019171B1 (en) | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) | |
KR101624752B1 (ko) | Akt 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄 | |
CA2900303A1 (en) | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 | |
BR112019014235A2 (pt) | Inibidores bicíclicos de histona desacetilase | |
CN100441581C (zh) | 1-[烷基],1-[(杂芳基)烷基]及1-[(芳基)烷基]-7-(嘧啶-4-基)-咪唑并[1,2-a]嘧啶-5(1H)-酮衍生物 | |
CN101676287A (zh) | 用作抗癫痫药的6-(取代苯氧基)-四唑并[5,1-a]酞嗪衍生物及其可药用盐 | |
BR112021012950A2 (pt) | Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb | |
US10059671B2 (en) | Positive allosteric modulators of mGluR3 | |
CN104710327A (zh) | 有益于治疗中枢神经系统疾病和病症的化合物 | |
CN102112469A (zh) | 神经元nAChR的安静减敏剂及其使用方法 | |
CN101506148A (zh) | Glyt-1的抑制剂 | |
CN109293566A (zh) | 酰胺类衍生物及其应用 | |
CN101817819A (zh) | 用作抗抑郁药的5-烷氧基-四唑并[1,5-a]喹啉酮衍生物及其可药用盐 | |
TW201035081A (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
CN104177324A (zh) | 呫吨酮类化合物及其抗抑郁用途 | |
KR101527803B1 (ko) | 신규한 헤테로사이클릭다이온 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 뇌신경세포 보호용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN ACTIS SUNTECH TECHNOLOGY DEVELOPMENT CO., LT Free format text: FORMER OWNER: QUAN ZHESHAN Effective date: 20110805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 133000 YANBIAN KOREAN AUTONOMOUS PREFECTURE, JILIN PROVINCE TO: 130033 CHANGCHUN, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110805 Address after: 130033 No. 1433, Zhanjiang Road, Changchun economic and Technological Development Zone, Jilin, China Patentee after: JILIN YINGLIANSHANGDE TECHNOLOGY DEVELOPMENT CO., LTD. Address before: Yanji City, Jilin province 133000 Station Street No. 121 Patentee before: Quan Zheshan |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091223 Termination date: 20180126 |
|
CF01 | Termination of patent right due to non-payment of annual fee |